By Fran Kritz
This story was updated on May 15 at 4:45 p.m. The CDC director accepted the ACIP recommendations.
The FDA and CDC recently issued a joint advisory statement recommending a pause in the use of the chikungunya vaccine, live (Ixchiq, Valneva SE), in people 60 years of age and older, while they investigate reports of serious adverse events (AEs).
Ixchiq, approved by the FDA in November 2023, is the first of two vaccines recently approved by the FDA to prevent chikungunya. In